Comparison of 3% saline versus normal saline as a diluent for nebulization in hospitalized children with acute bronchiolitis: A randomized clinical trial

Lalrammuana Hmar, Sarita Brahmacharimayum, Namganglung Golmei, M. Moirangthem, Shyamsunder Chongtham
{"title":"Comparison of 3% saline versus normal saline as a diluent for nebulization in hospitalized children with acute bronchiolitis: A randomized clinical trial","authors":"Lalrammuana Hmar, Sarita Brahmacharimayum, Namganglung Golmei, M. Moirangthem, Shyamsunder Chongtham","doi":"10.4103/jms.jms_43_20","DOIUrl":null,"url":null,"abstract":"Context: Bronchiolitis, the most common lower respiratory tract infection among infants and young children, is managed with a few clinically beneficial interventions. Hypertonic saline (HS) nebulization is suggested in the treatment of bronchiolitis, resulting in clinical improvement. Aim: The aim of the study was to compare the efficacy 3% HS versus 0.9% normal saline (NS) as nebulization diluent in children between 3 months and 2 years with acute bronchiolitis. Materials and Methods: In this prospective randomized controlled study, 158 admitted children between 3 months and 2 years with acute bronchiolitis were assigned into two groups – 3% HS and NS. Outcome variables were improvement in clinical severity (CS) score and length of hospital stay (LOS). Descriptive statistics such as mean, median, standard deviation, and percentages were used. Chi-square and t-tests were used to determine associations. Data analysis was performed using SPSS IBM version 21. Results: Baseline CS scores were similar – 3.98 ± 1.20 and 3.75 ± 1.06 for HS and NS groups (P = 0.209), respectively, but from the 2nd day of treatment, it decreased to 2.21 ± 1.10 for HS and 3.05 ± 1.17 for NS group (P ≤ 0.001), further reducing to 1.46 ± 0.63 for HS group and 2.01 ± 0.99 for NS group (P ≤ 0.001). Length of stay was also reduced: 4.98 ± 1.35 for the HS group compared to 5.84 ± 1.18 for the NS group (P ≤ 0.001). Conclusion: Using 3% HS instead of NS as a diluent for nebulization decreases clinical symptoms acute bronchiolitis besides the length of hospital stay.","PeriodicalId":39636,"journal":{"name":"JMS - Journal of Medical Society","volume":"34 1","pages":"86 - 90"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMS - Journal of Medical Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jms.jms_43_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Context: Bronchiolitis, the most common lower respiratory tract infection among infants and young children, is managed with a few clinically beneficial interventions. Hypertonic saline (HS) nebulization is suggested in the treatment of bronchiolitis, resulting in clinical improvement. Aim: The aim of the study was to compare the efficacy 3% HS versus 0.9% normal saline (NS) as nebulization diluent in children between 3 months and 2 years with acute bronchiolitis. Materials and Methods: In this prospective randomized controlled study, 158 admitted children between 3 months and 2 years with acute bronchiolitis were assigned into two groups – 3% HS and NS. Outcome variables were improvement in clinical severity (CS) score and length of hospital stay (LOS). Descriptive statistics such as mean, median, standard deviation, and percentages were used. Chi-square and t-tests were used to determine associations. Data analysis was performed using SPSS IBM version 21. Results: Baseline CS scores were similar – 3.98 ± 1.20 and 3.75 ± 1.06 for HS and NS groups (P = 0.209), respectively, but from the 2nd day of treatment, it decreased to 2.21 ± 1.10 for HS and 3.05 ± 1.17 for NS group (P ≤ 0.001), further reducing to 1.46 ± 0.63 for HS group and 2.01 ± 0.99 for NS group (P ≤ 0.001). Length of stay was also reduced: 4.98 ± 1.35 for the HS group compared to 5.84 ± 1.18 for the NS group (P ≤ 0.001). Conclusion: Using 3% HS instead of NS as a diluent for nebulization decreases clinical symptoms acute bronchiolitis besides the length of hospital stay.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
3%生理盐水与生理盐水雾化吸入治疗急性毛细支气管炎住院儿童的比较:一项随机临床试验
背景:毛细支气管炎是婴幼儿中最常见的下呼吸道感染,通过一些临床有益的干预措施进行治疗。高渗生理盐水(HS)雾化治疗细支气管炎,疗效显著。目的:本研究的目的是比较3% HS与0.9%生理盐水(NS)作为雾化器稀释剂对3个月至2岁急性毛细支气管炎患儿的疗效。材料和方法:在这项前瞻性随机对照研究中,158名3个月至2岁的急性细支气管炎患儿被分为两组:3% HS组和3% NS组。结果变量为临床严重程度(CS)评分和住院时间(LOS)的改善。使用了描述性统计,如平均值、中位数、标准差和百分比。采用卡方检验和t检验确定相关性。使用SPSS IBM version 21进行数据分析。结果:HS组和NS组的CS基线评分相似,分别为3.98±1.20和3.75±1.06 (P = 0.209),但从治疗第2天开始,HS组CS基线评分分别降至2.21±1.10和3.05±1.17 (P≤0.001),HS组CS基线评分进一步降至1.46±0.63和2.01±0.99 (P≤0.001)。HS组的住院时间为4.98±1.35,NS组为5.84±1.18 (P≤0.001)。结论:用3% HS代替NS作为稀释剂雾化治疗急性毛细支气管炎,可减少临床症状,缩短住院时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JMS - Journal of Medical Society
JMS - Journal of Medical Society Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
0
期刊最新文献
Dyserythropoiesis: A morphology-based study on bone marrow specimens The management of fatal hyperhemolysis in a sickle cell anemia patient transfused in a remote Island in North Andaman Usefulness of exercise stress test in early diagnosis of coronary artery disease in diabetic patients An investigation into the use of an extended lipid panel in the screening of cardiovascular events Estimation of systemic and mucosal toll-like receptors 4 and 6 in women with breast tumor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1